4-Aminoindazolyl-dihydrofuro[3,4- d ]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase
作者:Emily J. Hanan、Matt Baumgardner、Marian C. Bryan、Yuan Chen、Charles Eigenbrot、Peter Fan、Xiao-Hui Gu、Hank La、Shiva Malek、Hans E. Purkey、Gabriele Schaefer、Stephen Schmidt、Steve Sideris、Ivana Yen、Christine Yu、Timothy P. Heffron
DOI:10.1016/j.bmcl.2015.11.078
日期:2016.1
The treatment of epidermal growth factor receptor (EGFR)-driven non-small cell lung cancers with the T790M resistance mutation remains a significant unmet medical need. We report the identification of 4-aminoindazolyl-dihydrofuro[3,4-d] pyrimidines as non-covalent inhibitors of EGFR, with excellent activity against the T790M resistance double mutants and initial single activating mutants. Using an optimization strategy focused on structure-based design and improving PK properties through metabolite identification, we obtained advanced leads with high oral exposure. (C) 2015 Elsevier Ltd. All rights reserved.